Clinical Trials Logo

Filter by:
NCT ID: NCT03959722 Completed - Clinical trials for Gastrointestinal Symptoms

The Effect of Probiotics on GI Symptoms

WHOMLF
Start date: November 19, 2019
Phase: N/A
Study type: Interventional

A double-blind randomized, placebo-controlled study will be performed with experienced endurance athletes to assess the effect of probiotics supplementation on the occurrence and intensity of the gastrointestinal symptoms, on performance and on the composition and function of the gut microbiota. The duration of the supplementation period, with Ecologic® PERFORMANCE supplements, is fourteen weeks. Standardized maximum exercise tests on a treadmill are performed before and after the supplementation period, as well as two performance tests (before) and one performance test (after). During the performance tests, the load is first submaximal for 1 hour, after which a time trial of 30 minutes will be performed. The measurements before and after the supplementation period are performed on individual days with at least 48 hours of relative rest in between. During the supplementation period, training diaries, a Profile of Mood States (POMS) questionnaire and a few questionnaires about dietary habits will be completed.

NCT ID: NCT03959527 Active, not recruiting - Gonorrhea Clinical Trials

Zoliflodacin in Uncomplicated Gonorrhoea

Start date: November 6, 2019
Phase: Phase 3
Study type: Interventional

This trial is a multi-center, open label, randomized controlled, non-inferiority phase III trial evaluating the safety and efficacy of a 3 g oral dose of zoliflodacin compared to a combination of a single intra-muscular 500 mg dose of ceftriaxone and a single 1 g oral dose of azithromycin for the treatment of uncomplicated gonorrhoea.

NCT ID: NCT03958604 Active, not recruiting - Low Back Pain Clinical Trials

Burst Neurostimulation for Discogenic Low Back Pain

Start date: May 28, 2019
Phase: N/A
Study type: Interventional

The purpose of this prospective post market pilot study is to evaluate the effect of Burst Spinal Cord Stimulation(B-SCS) in the management of chronic discogenic pain in subjects who are refractory to other available treatments. Selected subjects will not be suitable candidates for lumbar spinal surgery and will meet the standard selection process for SCS as routinely utilized in the study centers. Results from this pilot study will inform current clinical practice and future comparative studies in this specific population. Eligible subjects for B-SCS will be asked to participate in this study. If they decide to participate, they will be treated with the Prodigy TM and Proclaim TM (Abbott Laboratories) SCS system and prospectively followed for 12 months following implantation.

NCT ID: NCT03958357 Completed - Cervical Cancer Clinical Trials

Post Market Clinical Follow-up Study Venezia

Start date: April 10, 2019
Phase:
Study type: Observational

The investigational device is the Advanced Gynecological Applicator (AGA) Venezia configuration, an applicator to treat locally advanced stage cervical cancer. The goal of the study is to assess the performance and the unknown risks or complications of the AGA Venezia configuration during clinical use of the applicator.

NCT ID: NCT03957031 Completed - Cancer, Gastric Clinical Trials

Gastric Cancer Risk Factors Associated With EU and CELAC Populations

LEGACY-1
Start date: May 31, 2019
Phase:
Study type: Observational

The study uses a case-control design that examines the differences in types of exposures between cases defined with a pathological confirmation of GC diagnosis, and controls, defined as patients to whom a gastroscopy was indicated and confirmed absent of GC i

NCT ID: NCT03956849 Recruiting - Clinical trials for Overweight and Obesity

Talking With Children About Weight and Lifestyle

Start date: February 13, 2019
Phase:
Study type: Observational

Obesity among children is a major problem. Therefore, it is important to start promoting a healthy lifestyle in an early stage. However, professionals find it difficult to start a conversation about overweight and lifestyle. Within Centre for Overweight Adolescent and Children's Healthcare (COACH) at the Maastricht University Medical Centre (MUMC+) a tool was developed, based on motivational interviewing, to help professionals engage in conversation with the children about weight and lifestyle. The aim of this study is to identify barriers and facilitators perceived by professionals, working with children, to start a conversation with a child with overweight or obesity about weight and lifestyle. In addition, this study researches the effects of the developed COACH Conversationstarter, a tool that can help healthcare professionals to start a conversation with children about overweight and lifestyle and to gain more insight in the views, thoughts and beliefs of the child and its family.

NCT ID: NCT03955445 Recruiting - C3 Glomerulopathy Clinical Trials

Long-term Efficacy, Safety and Tolerability of LNP023 in C3G

Start date: October 3, 2019
Phase: Phase 3
Study type: Interventional

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy

NCT ID: NCT03954574 Recruiting - Clinical trials for Pulmonary Circulation Diseases

Pulmonary Hemodynamics During Exercise - Research Network

PEX-NET
Start date: December 1, 2018
Phase:
Study type: Observational [Patient Registry]

The purpose of this Clinical Research Collaboration is to investigate the prognostic implications of pulmonary hemodynamics during exercise based on a large scale multi-centre approach by using retrospective and prospective analysis of hemodynamic data.

NCT ID: NCT03953846 Recruiting - Knee Osteoarthritis Clinical Trials

NUsurface Implant Registry

NIR
Start date: June 1, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of this active post-market surveillance clinical registry study is to further characterize the therapeutic effect, the long-term safety and effectiveness of the NUsurface® meniscus implant in the real-world post-marketing setting

NCT ID: NCT03953456 Terminated - Clinical trials for Non-Alcoholic Fatty Liver

Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Start date: August 16, 2019
Phase: Phase 2
Study type: Interventional

This randomized, double-blind, cross-over (placebo or elafibranor [GFT505]) placebo-controlled study, will evaluate the effect on hepatic lipid composition and safety of elafibranor 120 mg quaque die (QD) versus placebo in an adult NAFL population after 6 weeks of treatment with a 4-week wash-out period. This study will achieve mechanistic information about the mode of action of Elafibranor on the (lipid) metabolism in the human fatty liver